Halobetasol
- Atc Codes:D07AC21
- CAS Codes:66852-54-8#98651-66-2
- PHARMGKB ID:66852-54-8#98651-66-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Ultravate; USA: Halobetasol Propionate, Ultravate.
Drug combinations
Chemistry
Halobetasol Propionate: C~25~H~31~ClF~2~O~5~. Mw: 484.96. (1) Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6α,11β,16β)-; (2) 21-Chloro-6α,9-difluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate. CAS-66852-54-8; CAS-98651-66-2 (halobetasol)(1990).
Pharmacologic Category
Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Topical Corticosteroid. (ATC-Code: D07AC21).
Mechanism of action
Corticosteroids inhibit initial manifestations of inflammatory process (i.e. capillary dilation and edema, fibrin deposition, and migration and diapedesis of leukocytes into inflamed site) as well as later sequelae (angiogenesis, fibroblast proliferation).
Therapeutic use
Relief of inflammatory and pruritic manifestations of corticosteroid-response dermatoses.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to halobetasol or any component of the formulation. Viral, fungal, or tubercular skin lesions.
Warnings and precautions
Systemic absorption of topical corticosteroids may cause HPA axis suppression (reversible) particularly in younger children. Allergic contact dermatitis can occur. Prolonged treatment with corticosteroids associated with development of Kaposi’s sarcoma (case reports). Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and HPA suppression may occur when used on large surface areas, for prolonged periods, or with occlusive dressing.